Programmed death-ligand expression and lymph nodeinvolvement in penile squamous cell carcinoma

被引:0
|
作者
Peyroteo, Ines [1 ]
Santos, Filipa [2 ]
Marialva, Celso [1 ]
Ramos, Rodrigo [1 ]
机构
[1] Portuguese Inst Oncol Lisbon, Urol, Lisbon, Portugal
[2] Portuguese Inst Oncol Lisbon, Pathol, Lisbon, Portugal
关键词
PD-L1; Penile carcinoma; Lymph node involvement; Prognostic biomarker; PD-L1; EXPRESSION; ANTIBODY; SAFETY; CANCER;
D O I
10.4081/aiua.2024.12856
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Our objective was to investigate the association between programmed death-ligand (PD-L1) immunoexpression measured as a combined positive score and clinical outcomes in penile SqCC. Materials and methods: We retrospectively reviewed all penile SqCC cases diagnosed in our institution between 2018 and 2023. PD-L1 immunohistochemistry was performed as a qualitative assay. Immunoexpression in both tumor and immune cells equal or superior to 1 was considered positive. Results: A total of 34 patients with conventional penile SqCC were included. Eleven cases were HPV-associated (32.4%). Twelve cases were PD-L1 CPS < 1 and twenty-two were PD-L1 CPS >= 1. Nine cases (32.4%) were PD-L1 CPS >= 1 and p16 positive, but this did not translate in worse clinicopathological features. Larger tumors (3.0 cm in PD-L1 CPS >= 1 vs 2.5 cm in PD-L1 CPS < 1; p = 0.662), vascular invasion (36.4% in PD-L1 CPS >= 1 vs. 25.0% in PD-L1 CPS < 1; p = 0.705) and perineural invasion (40.9% in PD-L1 CPS >= 1 vs. 16.7% in PD-L1 CPS < 1; p = 0.252) were associated with PD-L1 expression. Among the high-risk features, only lymph node involvement had statistical significance, with 14 out of 22 PD-L1 CPS >= 1 patients (63.6%) having lymph node metastases when lymphadenectomy was performed (p = 0.031). With a median follow-up of 16 months (IQR 27.5), PD-L1 CPS >= 1 patients had worse overall survival (53.4 months vs 75.9 months), but no statistical significance could be inferred (p = 0.188). Conclusions: It is noteworthy the clinical significance of lymph node involvement in PD-L1 CPS >= 1 cases and a trend towards worse overall survival in this group of patients.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Programmed death-ligand 1 expression in the immune compartment of colon carcinoma
    Yilmaz, Osman
    Pankaj, Amaya
    Neyez, Azfar
    Rickelt, Steffen
    Taylor, Martin
    Lang, Evan R.
    Leijsen, Lieve
    Dinaux, Anne
    Shroff, Stuti G.
    Crotty, Rory
    Zhang, M. Lisa
    Cerda, Sandra
    Zhao, Qing
    Ferrone, Cristina
    Ting, David T.
    Patil, Deepa T.
    Yilmaz, Omer
    Berger, David
    Deshpande, Vikram
    MODERN PATHOLOGY, 2022, 35 (11) : 1740 - 1748
  • [22] Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma
    Skala, Stephanie L.
    Liu, Tzu-Ying
    Udager, Aaron M.
    Weizer, Alon Z.
    Montgomery, Jeffrey S.
    Palapattu, Ganesh S.
    Siddiqui, Javed
    Cao, Xuhong
    Fields, Kristina
    Abugharib, Ahmed E.
    Soliman, Moaaz
    Hafez, Khaled S.
    Miller, David
    Lee, Cheryl T.
    Alva, Ajjai
    Chinnaiyan, Arul M.
    Morgan, Todd M.
    Spratt, Daniel E.
    Jiang, Hui
    Mehra, Rohit
    EUROPEAN UROLOGY FOCUS, 2017, 3 (4-5): : 502 - 509
  • [23] The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma
    Akutsu, Yasunori
    Murakami, Kentaro
    Kano, Masayuki
    Toyozumi, Takeshi
    Matsumoto, Yasunori
    Takahashi, Masahiko
    Otsuka, Ryota
    Sekino, Nobufumi
    Yokoyama, Masaya
    Shiraishi, Tadashi
    Matsubara, Hisahiro
    ESOPHAGUS, 2018, 15 (02) : 103 - 108
  • [24] The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma
    Yasunori Akutsu
    Kentaro Murakami
    Masayuki Kano
    Takeshi Toyozumi
    Yasunori Matsumoto
    Masahiko Takahashi
    Ryota Otsuka
    Nobufumi Sekino
    Masaya Yokoyama
    Tadashi Shiraishi
    Hisahiro Matsubara
    Esophagus, 2018, 15 : 103 - 108
  • [25] Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma
    Song, Zhengbo
    Yu, Xinmin
    Zhang, Yiping
    LUNG CANCER, 2016, 99 : 166 - 171
  • [26] Morphometric analysis of nuclear shape irregularity as a novel predictor of programmed death-ligand 1 expression in lung squamous cell carcinoma
    Ryoko Saito-Koyama
    Keiichi Tamai
    Jun Yasuda
    Yasunobu Okamura
    Yuto Yamazaki
    Chihiro Inoue
    Yasuhiro Miki
    Jiro Abe
    Hisashi Oishi
    Ikuro Sato
    Hironobu Sasano
    Virchows Archiv, 2024, 484 : 609 - 620
  • [27] Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer
    Hosseini, Maryam Sadat
    Shafizadeh, Fatemeh
    Bahremani, Mohammad Hashemi
    Farzaneh, Farah
    Ashrafganjoei, Tahereh
    Arab, Maliheh
    Talayeh, Maryam
    Jafari, Fatemeh
    Abdshah, Alireza
    CANCER REPORTS, 2024, 7 (04)
  • [28] Morphometric analysis of nuclear shape irregularity as a novel predictor of programmed death-ligand 1 expression in lung squamous cell carcinoma
    Saito-Koyama, Ryoko
    Tamai, Keiichi
    Yasuda, Jun
    Okamura, Yasunobu
    Yamazaki, Yuto
    Inoue, Chihiro
    Miki, Yasuhiro
    Abe, Jiro
    Oishi, Hisashi
    Sato, Ikuro
    Sasano, Hironobu
    VIRCHOWS ARCHIV, 2024, 484 (04) : 609 - 620
  • [29] Altered Expression of Programmed Death-Ligand 1 after Neo-Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma
    Song, Zhengbo
    Zhang, Yiping
    Yu, Xinmin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1327 - S1328
  • [30] Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
    Mou, Haibo
    Yang, Qiu-an
    Yu, Lanfang
    Wang, Ting
    Liu, Kui
    Shen, Rong
    Pan, Xuedong
    Dai, Yi
    Wan, Qing
    Zhou, Fangling
    Qian, Lili
    Chen, Donglin
    Yau, Thomas
    Dong, Xiaowei
    Wang, Xuemei
    Wang, Shuang
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (09) : 2601 - 2609